Reach the Editorial Desk

What we respond to

This site welcomes feedback on three categories of inquiry:

Citation errors or broken links. If a referenced study's DOI resolves to the wrong paper, a PubMed link is dead, or a cited figure doesn't match the source, send a correction. We will verify and update.

New research. If a retatrutide Phase 2 or Phase 3 result has published and is not yet reflected here, a link to the primary publication is welcome.

Editorial feedback. If a page makes a claim that misrepresents the research, overstates the evidence, or mischaracterizes the compound's regulatory status, that feedback is taken seriously.

What we cannot respond to

This site does not provide medical advice and is not staffed by clinicians. Inquiries about personal health decisions, dosing, whether to try retatrutide, where to obtain it, or interactions with specific medications cannot be answered here — not because we are withholding information, but because those questions require a clinician who knows the individual asking.

Inquiries about sourcing, purchasing, or ordering retatrutide will not receive a response. This site does not sell, supply, or refer to suppliers of any compound.

This site does not respond to press inquiries, partnership proposals, or link-exchange requests.

Send a message

Use the form below to send an editorial note. Include the specific page URL and the claim in question if reporting an error. Include a DOI or PubMed link if submitting new research.

[contact form placeholder]

Response time: Editorial corrections are reviewed periodically. There is no guaranteed response timeline. If a correction is confirmed, the relevant page will be updated — the update will be visible in the page content without a separate email confirmation.